NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/21/2025
Back to search
Official data from USPTO
LOBA BIOTECH
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
32
Latest update
04/03/2026
Trademark type
Combined
Nice classes
1, 5, 40, 42
Filing date
10/05/2023
Registration date
02/11/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/11/2025
Last transaction
04/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
27
Owner location
AT
Examiner
MESSICK, TABITHA LEE
Law office
L40
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the word "LOBA" in light blue, followed by the word "BIOTECH" in dark blue. In between the wording is a stylized design resembling a helix and four circles in a mixture of light blue and dark blue. The white in the mark is for shading purposes and is not claimed as a feature of the mark.
Holders and representatives
Holders
Loba biotech GmbH
Representatives
Michael Fedrick Loza & Loza, LLP
Technical classification
Nice Classes
Class 1Class 5Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Biological preparations for scientific and research use in the fields of chemistrybiologybiotechnologybiopharmabiomedicinebiochemistry; diagnostic preparations for scientific or research use in the fields of chemistrybiologybiotechnologybiopharmabiomedicinebiochemistry; chemical reagents for quality control for diagnostics or for scientific purposesother than for medical or veterinary purposes
Class 5
Active pharmaceutical ingredients for use in drugs in the nature of biological materials and biotechnological materials for the treatment of infectious diseasesinflammationautoimmune diseasesproliferative disorders and cancer; bacterial preparations for medical and veterinary use; biological preparations for medical purposes for the treatment of infectious diseasesinflammationautoimmune diseasesproliferative disorders and cancer; enzyme preparations for medical purposes; enzymes for medical purposes; drug delivery agents using liposomesnanoparticlesfusion proteinsprotein-cage nanoparticles to facilitate the delivery of bacterial and enzyme preparations
Class 40
Custom manufacture and processing of chemicals and ingredients for pharmaceuticals; custom manufacture of bacteriological cultures and reagents; custom manufacture of goods for the pharmaceutical and consumer healthcare industry; custom manufacturing services for drugs
Class 42
Scientific research services in the fields of chemistrybiologybiotechnologybiopharmabiomedicinebiochemistry; scientific research services regarding high quality intermediates in the fields of chemistrybiologybiotechnologybiopharmabiomedicinebiochemistry; medical research and pharmaceutical research and development in the fields of chemistrybiologybiotechnologybiopharmabiomedicinebiochemistry; analytical services in the fields of chemistrybiologybiotechnologybiopharmabiomedicinebiochemistrychemical and biochemical analysisbiological and biopharmaceutical testingbiotechnological assessments in the fields of high-quality intermediates; microbiological analysis
Publications
History of USPTO decisions and trademark events.
32 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
09/19/2025
FICS
FINAL DISPOSITION NOTICE SENT TO IB
08/29/2025
FIMP
FINAL DISPOSITION PROCESSED
08/28/2025
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
07/26/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
07/07/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
07/07/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
05/12/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
02/11/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
02/11/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/24/2024
PUBO
PUBLISHED FOR OPPOSITION
12/24/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/18/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/27/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/05/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/05/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/05/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/19/2024
GNRT
NON-FINAL ACTION E-MAILED
09/19/2024
CNRT
NON-FINAL ACTION WRITTEN
09/19/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/14/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/13/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/13/2024
RFNT
REFUSAL PROCESSED BY IB
07/15/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/27/2024
RFRR
REFUSAL PROCESSED BY MPU
06/27/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/14/2024
CNRT
NON-FINAL ACTION WRITTEN
05/29/2024
DOCK
ASSIGNED TO EXAMINER
05/24/2024
MAFR
APPLICATION FILING RECEIPT MAILED
02/16/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/12/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
02/09/2024
Continuous trademark protection
Get notified about every new filing that threatens LOBA BIOTECH or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.